Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study
1 other identifier
observational
N/A
1 country
1
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity. Morbidity rates are estimated at 20% to 30% in Western adults, increasing to 90% in patients who are morbidly obese or diabetic. Risk factors in non-obese NAFLD patients are of especial practical and theoretical importance. Cholesterol Ester Storage Disease (CESD) is an autosomal recessive chronic disease of variable phenotype, caused by a deficiency in lysosomal acid lipase (LAL) and characterized by accumulation of fat in tissues and organs. Hepatic accumulation of fat in this disorder can cause hepatomegaly with varying degrees of damage varying from steatosis to fibrosis, elevated aminotransaminases, and isolated splenomegaly. Since the contribution of LAL deficiency to non-obese NAFLD is poorly understood, the investigators propose to evaluating the association between NAFLD and LAL deficiency in a prospective study in our population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 10, 2013
CompletedFirst Posted
Study publicly available on registry
February 15, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2014
CompletedFebruary 15, 2013
February 1, 2013
February 10, 2013
February 13, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
liver ultrasound, ultrasound Doppler of the common carotid artery, hepatic Fibroscan evaluation (transient elastography) for assessment of steatosis and fibrosis
year
Study Arms (1)
NAFLD
Eligibility Criteria
400 subjects will be enrolled and informed consent obtained. After clinical evaluation, subjects will undergo liver ultrasound, non-invasive liver elastography (Fibroscan) and standard biochemical evaluation including glucose, insulin, TG, HDL, LDL, leptin, adiponectin and TNF-alpha. They will then be divided into 2 groups: NAFLD, and NAFLD with fibrosis (NASH). In addition a cohort of healthy volunteers will also be studied. LAL activity in dry blood spots (DBS) will be measured using the substrate 4-methylumbelliferyl palmitate. LAL activity will be measured by measuring total lipase activity and lipase activity in the presence of Lalistat2.
You may qualify if:
- Age between 18-80 years;
- BMI 25-40;
- Fatty liver disease (bright liver, hepatomegaly by ultrasound (Liver span \> 15 cm mid clavicle line), splenomegaly (\>13 cm) or both.
You may not qualify if:
- Alcohol abuse\>30 gm/day, or \> 70 gram per week;
- Soft drink abuse;
- Drugs known to cause fatty liver;
- Chronic hepatitis (B and C);
- Biliary liver disease;
- Autoimmune hepatitis;
- HIV;
- Genetic/Metabolic liver disease (Wilson, alpha-1 antitrypsin, CF);
- Failure to give informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Assy Nimerlead
Study Sites (1)
Assy Nimer
Safed, Israel, 13100, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
February 10, 2013
First Posted
February 15, 2013
Primary Completion
February 1, 2014
Last Updated
February 15, 2013
Record last verified: 2013-02